These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35740636)

  • 81. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
    Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
    Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma.
    Iwaki T; Niimi A; Kano M; Kurokawa Y; Yoshizaki U; Nozaki K; Nomiya A; Miyazaki H; Kume H
    IJU Case Rep; 2021 Jan; 4(1):32-35. PubMed ID: 33426493
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution.
    Vila CM; Moreno FA; Estébanez MM; Ares GR; Villacampa G; Dashti P; Oberoi HS; Martin-Huertas R; Jares P; Alos L; Teixido C; Rull R; Sanchez M; Malvehy J; Carcelero E; Valduvieco I; Fernandez AA
    Clin Transl Oncol; 2022 Feb; 24(2):319-330. PubMed ID: 34420138
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
    Amaral T; Kiecker F; Schaefer S; Stege H; Kaehler K; Terheyden P; Gesierich A; Gutzmer R; Haferkamp S; Uttikal J; Berking C; Rafei-Shamsabadi D; Reinhardt L; Meier F; Karoglan A; Posch C; Gambichler T; Pfoehler C; Thoms K; Tietze J; Debus D; Herbst R; Emmert S; Loquai C; Hassel JC; Meiss F; Tueting T; Heinrich V; Eigentler T; Garbe C; Zimmer L;
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221017
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
    Engel Ayer Botrel T; Datz Abadi M; Chabrol Haas L; da Veiga CRP; de Vasconcelos Ferreira D; Jardim DL
    J Med Econ; 2021; 24(1):291-298. PubMed ID: 33538203
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy.
    Grossmann NC; Schuettfort VM; Pradere B; Rajwa P; Quhal F; Mostafaei H; Laukhtina E; Mori K; Motlagh RS; Aydh A; Katayama S; Moschini M; Fankhauser CD; Hermanns T; Abufaraj M; Mun DH; Zimmermann K; Fajkovic H; Haydter M; Shariat SF
    Urol Oncol; 2022 Mar; 40(3):106.e11-106.e19. PubMed ID: 34810077
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy.
    Carril-Ajuria L; Lora D; Carretero-González A; Martín-Soberón M; Rioja-Viera P; Castellano D; de Velasco G
    Clin Genitourin Cancer; 2021 Apr; 19(2):95-102. PubMed ID: 33189597
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.
    Wu B; Zhang Q; Sun J
    J Immunother Cancer; 2018 Nov; 6(1):124. PubMed ID: 30458884
    [TBL] [Abstract][Full Text] [Related]  

  • 89. PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.
    Buckley HL; Collinson FJ; Ainsworth G; Poad H; Flanagan L; Katona E; Howard HC; Murden G; Banks RE; Brown J; Velikova G; Waddell T; Fife K; Nathan PD; Larkin J; Powles T; Brown SR; Vasudev NS
    BMC Cancer; 2019 Nov; 19(1):1102. PubMed ID: 31727024
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The Predictive Value of Systemic Inflammatory Factors in Advanced, Metastatic Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab.
    Liu J; Gao D; Li J; Hu G; Liu J; Liu D
    Onco Targets Ther; 2022; 15():1161-1170. PubMed ID: 36238132
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab.
    De Giorgi U; Procopio G; Giannarelli D; Sabbatini R; Bearz A; Buti S; Basso U; Mitterer M; Ortega C; Bidoli P; Ferraù F; Crinò L; Frassoldati A; Marchetti P; Mini E; Scoppola A; Verusio C; Fornarini G; Cartenì G; Caserta C; Sternberg CN
    Clin Cancer Res; 2019 Jul; 25(13):3839-3846. PubMed ID: 30967420
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy.
    Sejima T; Masago T; Yoshida M; Nishi T; Kawabata Y; Tajima Y; Yumioka T; Honda M; Takenaka A
    Int Cancer Conf J; 2021 Oct; 10(4):285-289. PubMed ID: 34567939
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
    Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
    Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Saggi SS; McHenry MB; Motzer RJ
    ESMO Open; 2020 Nov; 5(6):e001079. PubMed ID: 33246931
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma.
    Numakura K; Sekine Y; Hatakeyama S; Muto Y; Sobu R; Kobayashi M; Sasagawa H; Kashima S; Yamamto R; Nara T; Akashi H; Tabata R; Sato S; Saito M; Narita S; Ohyama C; Habuchi T
    Cancer Med; 2023 Aug; 12(16):16837-16845. PubMed ID: 37403728
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC).
    Palacka P; Slopovsky J; Obertova J; Chovanec M; Rejlekova K; Sycova-Mila Z; Kollarik B; Mardiak J; Mego M
    Anticancer Res; 2021 Nov; 41(11):5749-5759. PubMed ID: 34732448
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.
    Tucker MD; Brown LC; Chen YW; Kao C; Hirshman N; Kinsey EN; Ancell KK; Beckermann KE; Davis NB; McAlister R; Schaffer K; Armstrong AJ; Harrison MR; George DJ; Rathmell WK; Rini BI; Zhang T
    Biomark Res; 2021 Nov; 9(1):80. PubMed ID: 34732251
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [A CASE OF RENAL CELL CARCINOMA WITH SMALL INTESTINE METASTASIS DURING NIVOLUMAB PLUS IPILIMUMAB].
    Karibe Y; Tabei T; Hayashi H; Sugimura R; Takizawa H; Terao H; Funahashi M; Ota J; Moriyama M
    Nihon Hinyokika Gakkai Zasshi; 2022; 113(3):110-114. PubMed ID: 37468276
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Expression of tertiary lymphoid structure in deferred cytoreductive nephrectomy of metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
    Sazuka T; Fujimoto A; Sato H; Arai T; Imamura Y; Sakamoto S; Ikeda JI; Ichikawa T
    IJU Case Rep; 2021 Nov; 4(6):355-358. PubMed ID: 34755054
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma.
    Teishima J; Murata D; Yukihiro K; Sekino Y; Inoue S; Hayashi T; Mita K; Hasegawa Y; Kato M; Kajiwara M; Shigeta M; Maruyama S; Moriyama H; Fujiwara S; Matsubara A
    Curr Urol; 2023 Mar; 17(1):52-57. PubMed ID: 37692134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.